Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial of pemigatinib in previously treated glioblastoma and other primary CNS tumors with FGFR1-3 alterations was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adult-type Diffuse Gliomas
• Glioblastoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Glioblastoma, Adult-type Diffuse Gliomas | Phase 2 | Status: TERMINATED | Results posted: 2025-12-30